Format

Send to

Choose Destination
J Clin Gastroenterol. 2013 Jul;47 Suppl:S47-9. doi: 10.1097/MCG.0b013e3182932e6f.

Hepatocellular carcinoma: perspective of an oncologist.

Author information

1
Department of Medicine, Yale University School of Medicine, Section of Medical Oncology, New Haven, CT 06520-8032, USA. stacey.stein@yale.edu

Abstract

The medical oncologist's perspective on hepatocellular carcinoma (HCC) is unique compared with their view on other solid tumors. A patient's underlying liver function should be factored into the selection of treatment options; therefore, a staging system that takes into account other clinical parameters other than only tumor characteristics is important. Sorafenib is currently the only FDA-approved chemotherapy drug for patients with HCC based on the data from the SHARP trial. It is important for oncologists to anticipate and treat the side effects of sorafenib treatment in order to help the patients continue the treatment. In addition, it is important to design clinical trials for HCC that have meaningful endpoints to improve our care for patients with HCC.

PMID:
23751802
DOI:
10.1097/MCG.0b013e3182932e6f
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center